Gastroprotection with proton-pump inhibitors in high-risk cardiovascular patients: who to target and for how long?

被引：3
|
作者：
Vaduganathan, Muthiah [1 ,2 ]
Pareek, Manan [1 ,2 ,3 ]
Bhatt, Deepak L. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Odense Univ Hosp, Ctr Individualized Med Arterial Dis CIMA, Dept Endocrinol, Cardiovasc & Metab Prevent Clin, Odense, Denmark
来源：
EXPERT OPINION ON DRUG SAFETY | 2016年 / 15卷 / 11期
关键词：
Cardiovascular safety; coronary artery disease; gastrointestinal bleeding; proton-pump inhibitors; LOW-DOSE ASPIRIN; DUAL ANTIPLATELET THERAPY; PERCUTANEOUS CORONARY; CONSENSUS DOCUMENT; CLOPIDOGREL; TRIAL;
D O I：
10.1080/14740338.2016.1227790
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1451 / 1453
页数：3
相关论文
共 50 条
  • [31] Severe hypomagnesaemia in long-term users of proton-pump inhibitors
    Cundy, T.
    Dissanayake, A.
    CLINICAL ENDOCRINOLOGY, 2008, 69 (02) : 338 - 341
  • [32] Proton-Pump Inhibitors Are Associated With Increased Cardiovascular Risk Independent of Clopidogrel Use A Nationwide Cohort Study
    Charlot, Mette
    Ahlehoff, Ole
    Norgaard, Mette Lykke
    Jorgensen, Casper H.
    Sorensen, Rikke
    Abildstrom, Steen Z.
    Hansen, Peter Riis
    Madsen, Jan Kyst
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar
    ANNALS OF INTERNAL MEDICINE, 2010, 153 (06) : 378 - 386
  • [33] Review article: the long-term use of proton-pump inhibitors
    Raghunath, AS
    O'Morain, C
    Mcloughlin, RC
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 : 55 - 63
  • [34] Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
    Janett, Simone
    Camozzi, Pietro
    Peeters, Gabriella G. A. M.
    Lava, Sebastiano A. G.
    Simonetti, Giacomo D.
    Simonetti, Barbara Goeggel
    Bianchetti, Mario G.
    Milani, Gregorio P.
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [35] Proton-pump inhibitors and risk of fractures: an update meta-analysis
    B. Zhou
    Y. Huang
    H. Li
    W. Sun
    J. Liu
    Osteoporosis International, 2016, 27 : 339 - 347
  • [36] Proton Pump Inhibitors: for What and for How Long
    Thakul Rattanasuwan
    Adonice P. Khoury
    Alex M. Ebied
    SN Comprehensive Clinical Medicine, 2020, 2 (6) : 719 - 726
  • [37] Do opioids, sedatives and proton-pump inhibitors increase the risk of fractures?
    Porsdottir, Guolaug
    Benedikz, Elisabet
    Porgeirsdottir, Sigriour A.
    Johannsson, Magnus
    LAEKNABLADID, 2017, 103 (05): : 231 - 235
  • [38] Optimizing cardiovascular and chemopreventive benefits of aspirin: what role for the proton-pump inhibitors?
    Scheiman, J
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 : 7 - 8
  • [39] Proton-pump inhibitors and risk of fractures: an update meta-analysis
    Zhou, B.
    Huang, Y.
    Li, H.
    Sun, W.
    Liu, J.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) : 339 - 347
  • [40] Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects
    Pasternak, Bjorn
    Hviid, Anders
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2011, 66 (04) : 195 - 197
12345